

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended) An isolated or purified peptide ~~or a partial sequence of said peptide having cell death inhibitory activity,~~ said peptide ~~or said partial sequence of peptide~~ having cell death-inhibitory activity comprising the amino acid sequence consisting of 103 amino acid residues at the C-terminal of selenoprotein P, ~~or having said amino acid sequence with one or several amino acid residues therein being deleted, substituted or added, or having a partial sequence of either of the above amino acid sequences and having cell death inhibitory activity.~~

2. (Currently Amended) The isolated or purified peptide ~~or partial sequence of said peptide~~ of claim 1, having the amino acid sequence of the formula (I):

Lys Arg Cys Ile Asn Gln Leu Leu Cys Lys Leu Pro Thr Asp Ser Glu Leu
Ala Pro Arg Ser Xaa Cys Cys His Cys Arg His Leu (SEQ ID NO:1)

and/or the formula (II):

Thr Gly Ser Ala Ile Thr Xaa Gln Cys Lys Glu Asn Leu Pro Ser Leu Cys
Ser Xaa Gln Gly Leu Arg Ala Glu Glu Asn Ile (SEQ ID NO:2)

wherein Xaa is selenocysteine, ~~or a partial sequence of the amino acid sequence having cell death inhibitory activity of the amino acid sequences of formulas (I) or (II).~~

3. (Currently Amended) The isolated or purified peptide ~~or partial sequence of said peptide~~ of claim 1 or 2 wherein said peptide ~~or partial sequence of said peptide are~~ is derived from plasma proteins.

4. (Currently Amended) The isolated or purified peptide ~~or partial sequence of said peptide~~ of claim 1, wherein said peptide ~~or partial sequence of said peptide~~ (a) ~~are~~ is recovered in fractions of molecular weight 10 kDa to 30 kDa by molecular size fractionation with membrane; (b) ~~have~~ has structures showing isoelectric points at between pH 7 and pH 8 and at pH 8 or more in blood as a result of testing of binding to ion exchange resin; (c) ~~show~~ shows two bands at molecular weight 13 to 14 kDa and two bands at 16 to 17 kDa, the latter being a glycosylated form of the former, in non-reductive SDS-PAGE; and (d) ~~have~~ has a band ~~pattern~~ pattern of 3 to 4 kDa, 7 to 9 kDa and 10 to 12 kDa in SDS-PAGE under reductive condition in addition to the bands (c).

5. (Currently Amended) The isolated or purified peptide ~~or partial sequence of said peptide~~ of claim 1, wherein said peptide ~~or partial sequence of said peptide correspond~~ corresponds to the bands at 3 to 4 kDa, 7 to 9 kDa and 10 to 12 kDa in SDS-PAGE under reductive condition.

6. (Currently Amended) A medicament for ~~preventing or~~ treating diseases related to cell death, comprising as an active ingredient the isolated or purified peptide ~~or partial sequence of said peptide having the cell death inhibitory activity~~ of claim 1.

7. (Previously Presented) The medicament of claim 6 wherein said diseases are selected from AIDS, Parkinson's disease, Alzheimer's disease, arteriosclerosis, and diseases in which reperfusion injury is observed.

8. (Currently Amended) A medicament for ~~preventing or~~ treating diseases related to oxidation/reduction reaction, comprising as an active ingredient the isolated or purified peptide ~~or partial sequence of said peptide having the cell death inhibitory activity~~ of claim 1.

9. (Currently Amended) A medicament for ~~preventing or~~ treating diseases in which the immune system is involved, comprising as an active ingredient the isolated or purified peptide ~~or partial sequence of said peptide having the cell death-~~ ~~inhibitory activity~~ of claim 1.

10. (Currently Amended) An additive for cell culture comprising as an active ingredient the isolated or purified peptide ~~or partial sequence of said peptide having the cell death-~~ ~~inhibitory activity~~ of claim 1.

11. (Original) A method for screening a cell death-inhibitory activity which comprises adding a candidate substance suspected of having a cell death-inhibitory activity to human megakaryoblast culture system with serum free medium supplemented with 0.01 to 0.5% albumin in which sudden cell death is observed, and estimating an extent of cell death inhibition induced thereby.

12-15. (cancelled)

16. (Previously Presented) The medicament of claim 7, wherein said diseases in which reperfusion injury is observed are selected

Appl. No. 10/856,199

from the group consisting of myocardial infarction, cerebral infarction and organ transplantation.